Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Transient elimination of B lymphocytes with anti-CD20 monoclonal antibody would decrease
immune-mediated destruction of beta cells and result in preserved beta-cell function in
patients with type 1 diabetes of recent onset.